A new Office of Strategy and Growth will identify opportunities for future growth that are distinct from those being pursued by the company’s existing businesses. A Surgical Care Group will focus on advancing technologies, solutions and services to enhance patient care in the surgical setting and a Comprehensive Care Group will create portfolios to address some of the world’s most chronic and pervasive conditions, such as metabolic disorders, through the convergence of technologies, products and services.
The Office of Strategy and Growth will be led by Nicholas Valeriani, currently worldwide chairman, Medical Devices and Diagnostics. The new office will identify new growth opportunities distinct from existing pursuits that are strategic fits for Johnson & Johnson and that have the potential for significant impact on human health. As part of his role, Mr Valeriani will assume responsibility for the Johnson & Johnson Development Corporation, the corporate office of science and technology, and worldwide operations. The devices and diagnostics companies currently under Mr Valeriani’s leadership will serve as the foundations for two new business operating groups, surgical Care and comprehensive Care.
Sherilyn McCoy, currently company group chairman for Ethicon, will assume the role of worldwide chairman, Surgical Care, and will become a member of the executive committee of Johnson & Johnson, reporting to the CEO. Franchises comprising the Surgical Care Group will include Ethicon, Ethicon Endo-Surgery and DePuy.
Donald Casey, Jr., currently company group chairman for the diabetes franchise that includes LifeScan and Animas, will assume the role of worldwide chairman, Comprehensive Care, and will become a member of the executive Committee, reporting to the CEO. Franchises comprising the Comprehensive Care Group will include Diabetes, Cordis, Johnson & Johnson Vision Care and Ortho-Clinical Diagnostics. Each of the new organizations and appointments become effective, January 1, 2008.